Search
for
Sort by
Research 30 of 1000+
- Management of Dermatologic Toxicities
- 307 Dermatologic toxicities associated with chronic gamma-secretase inhibitor treatment for desmoid tumor
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- MARIO LACOUTURE: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
- Dermatological adverse events with taxane chemotherapy
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- P164 Cutaneous toxicities occurring during amivantamab treatment: the experience of a single large specialist institution
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
- Effect of a medicinal and edible decoction YH0618 on chemotherapy-induced dermatologic toxicity: a randomized controlled trial
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- ASSESSMENT OF SOCIODEMOGRAPHIC CHARACTERISTICS AND COMPARATIVE ANALYSIS OF ADVERSE DRUG REACTIONS AMONG OROPHARYNGEAL CANCER PATIENTS RECEIVING DIFFERENT CHEMOTHERAPEUTIC REGIMENS IN KARACHI, SINDH, PAKISTAN
- Cutaneous adverse effects of targeted therapies
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Prophylaxis and Management of Skin Toxicities
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Clinical development and management of adverse events associated with FGFR inhibitors
- Chemotherapy-related adverse effects with anthracycline and taxane-containing regimens in patients with localized Breast cancer: a descriptive study
- Cutaneous toxicities of new treatments for melanoma
- Management of Toxicities of Targeted Therapies
- Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies
- Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
- Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies